Schering GMP Criminal Investigation Continues After Consent Decree
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough faces a potential criminal case regarding GMP violations after finalizing a consent agreement with FDA May 17
You may also be interested in...
Schering CEO Hassan Will Add Personal Touch To Allergy Business Turnaround
Schering-Plough CEO Fred Hassan will be directly involved in reviving the firm's declining allergy business following the Rx-to-OTC switch of Claritin in December 2002
Schering Plans For Possible Clarinex Switch By Readying OTC Division
Preparations for a possible Rx-to-OTC switch of Clarinex (desloratadine) will be directed by Schering Consumer Health Care Division Chairman Stanley Barshay
Schering NDAs Not Subject To Extra Scrutiny Under FDA Consent Decree
Schering-Plough's pending supplemental NDAs to switch Claritin (loratadine) OTC appear to be unaffected by the company's GMP consent decree with FDA